

Aaron Cumpston

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7073974/publications.pdf>

Version: 2024-02-01

26
papers

261
citations

1163117

8
h-index

940533

16
g-index

26
all docs

26
docs citations

26
times ranked

500
citing authors

#	ARTICLE	IF	CITATIONS
1	Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4424-4428.	3.2	60
2	A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 266-269.	2.5	57
3	Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. <i>Cytotherapy</i> , 2015, 17, 1785-1792.	0.7	30
4	Predictors and Impact of Thirty-Day Readmission on Patient Outcomes and Health Care Costs after Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 415-420.	2.0	16
5	Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. <i>Leukemia Research and Treatment</i> , 2017, 2017, 1-6.	2.0	16
6	Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 557-561.	2.5	14
7	Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. <i>Bone Marrow Research</i> , 2013, 2013, 1-8.	1.7	10
8	Evaluation of Extended Interval Dosing Aminoglycosides in the Morbidly Obese Population. <i>Advances in Pharmacological Sciences</i> , 2013, 2013, 1-5.	3.7	9
9	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1295-1302.	2.0	8
10	Single versus double-unit transfusion: Safety and efficacy for patients with hematologic malignancies. <i>European Journal of Haematology</i> , 2019, 102, 383-388.	2.2	8
11	Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1773-1780.	2.0	7
12	Higher Infused CD34+ Cell Dose Improves Survival In Patients Undergoing In Vivo T-Cell Depleted, but Not T-Cell Replete Peripheral Blood Hematopoietic Cell Transplant. <i>Blood</i> , 2010, 116, 1272-1272.	1.4	6
13	Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Blood</i> , 2012, 120, 1942-1942.	1.4	6
14	Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Advances in Hematology</i> , 2017, 2017, 1-4.	1.0	5
15	Evaluation of the Pharmacokinetic Interaction Between Letemovir and Tacrolimus in Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 371.e1-371.e4.	1.2	5
16	Tacrolimus Dose Modification in Hematopoietic Cell Transplant Recipients Following a Change in Therapy from Fluconazole to Voriconazole. <i>ISRN Transplantation</i> , 2013, 2013, 1-5.	0.2	2
17	Prospective assessment of <i>Clostridioides</i> (formerly <i>Clostridium</i>) <i>difficile</i> colonization and acquisition in hematopoietic stem cell transplant patients. <i>Transplant Infectious Disease</i> , 2020, 22, e13438.	1.7	1
18	Impact of anti-aerobic antibiotic activity on graft-versus-host disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients at an institution that utilizes antibiotic cycling. <i>Transplant Infectious Disease</i> , 2021, 23, e13676.	1.7	1

#	ARTICLE	IF	CITATIONS
19	Effect of T-Cell Dose On Outcomes After Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Hematological Malignancies.. Blood, 2009, 114, 1171-1171.	1.4	0
20	Clofarabine In Combination with Cyclophosphamide for Treatment of Relapsed/Refractory Acute Leukemia In Adult Patients. Blood, 2010, 116, 4367-4367.	1.4	0
21	In Vivo T-Cell Depletion Does Not Improve Rates of Graft-Versus-Host Disease and Transplantation Outcomes In Patients Undergoing Peripheral Blood Hematopoietic Cell Transplant.. Blood, 2010, 116, 4536-4536.	1.4	0
22	Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Blood, 2010, 116, 1347-1347.	1.4	0
23	Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies â€œ A Multicenter Analysis. Blood, 2011, 118, 313-313.	1.4	0
24	Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies â€œ A Multicenter Analysis. Blood, 2012, 120, 4409-4409.	1.4	0
25	Predictors and Impact Of 30-Day Readmissions On Patient Outcomes and Healthcare Costs After Allogeneic Hematopoietic Cell Transplantation. Blood, 2013, 122, 1718-1718.	1.4	0
26	A prospective study of filgrastim pharmacokinetics in morbidly obese patients compared with nonâ€œobese controls. Pharmacotherapy, 2021, 42, 53.	2.6	0